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Monte Carlo (MC) codes are increasingly spreading in the hadrontherapy community
due to their detailed description of radiation transport and interaction with matter. The 
suitability of a MC code for application to hadrontherapy demands accurate and reliable 
physical models capable of handling all components of the expected radiation field.
This becomes extremely important for correctly performing not only physical but also
biologically based dose calculations, especially in cases where ions heavier than pro-
tons are involved. In addition, accurate prediction of emerging secondary radiation is of 
utmost importance in innovative areas of research aiming at in vivo treatment verification. 
This contribution will address the recent developments of the FLUKA MC code and
its practical applications in this field. Refinements of the FLUKA nuclear models in the 
therapeutic energy interval lead to an improved description of the mixed radiation field as 
shown in the presented benchmarks against experimental data with both 4He and 12C ion 
beams. Accurate description of ionization energy losses and of particle scattering and 
interactions lead to the excellent agreement of calculated depth–dose profiles with those 
measured at leading European hadron therapy centers, both with proton and ion beams. 
In order to support the application of FLUKA in hospital-based environments, Flair, the 
FLUKA graphical interface, has been enhanced with the capability of translating CT
DICOM images into voxel-based computational phantoms in a fast and well-structured 
way. The interface is capable of importing also radiotherapy treatment data described in 
DICOM RT standard. In addition, the interface is equipped with an intuitive PET scanner 
geometry generator and automatic recording of coincidence events. Clinically, similar
cases will be presented both in terms of absorbed dose and biological dose calculations 
 
 
 
 
 
 
describing the various available features.
Keywords: Monte carlo, simulation, hadrontherapy
1. inTrODUcTiOn
Popularity of Monte Carlo (MC) techniques in the field of medical physics is increasing rapidly 
in recent years. This is specifically the case for hadron therapy. MC simulations are an essential 
tool for the design and commissioning of novel clinical facilities, allowing a detailed description 
of the beam line and the delivery system. They are also widely used for bunker design, shielding, 
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and radiation protection. MC calculations are a valuable tool 
for the commissioning of Treatment Planning Systems (TPSs). 
Furthermore, MC codes can represent a unique  instrument for 
validation, and possibly the improvement, of analytical TPS’s. 
In situations where experimental validation is unavailable and/
or analytical methods are inadequate, MC simulation allows 
patient-specific dose calculation. Aspects where MC techniques 
can be more effective compared to traditional, analytical methods 
may be summarized as follows:
•	 MC methods take into account more realistically the 
 composition of the human body (1–3), with a possible advan-
tage over the water-equivalent approach typically used in 
analytical TPS’s.
•	 MC methods naturally include mixed field description and 
three-dimensional spread of the particle fluence, reliably 
describing the transport, and the interaction of the primary 
beam and of the secondaries (4, 5).
•	 In-beam monitoring of the irradiation through positron emis-
sion tomography or the detection of prompt photons from 
nuclear de-excitation can be performed using MC simulations, 
taking into full account the complexity of the mixed radiation 
field and tissue stoichiometry (3, 6–8).
The FLUKA code (8, 9) is a general purpose Monte Carlo 
code simulating the interaction and transport of hadrons, heavy 
ions, and electromagnetic particles. It is jointly developed by 
the European Organization for Nuclear Research (CERN) and 
the Italian Institute for Nuclear Physics (INFN). It is built and 
maintained with the best possible physical models in terms of 
completeness and accuracy. This approach, usually defined as 
microscopic, allows sound physical bases to be given to each 
step. Performance is optimized comparing with particle produc-
tion data at the single interaction level. No tuning whatsoever 
on integral data, like calorimeter resolutions, thick target yields, 
etc., is performed. Therefore, final predictions are obtained with 
a minimal set of free parameters, fixed for all energies and target/
projectile combinations. Results in complex cases as well as scal-
ing laws and properties emerge naturally from the underlying 
physical models and the basic conservation laws are fulfilled 
a priori. Moreover, the microscopic approach preserves correla-
tions within interactions and among the shower components, and 
it provides predictions where no experimental data are directly 
available. When needed, powerful biasing techniques are avail-
able to reduce computing time. Descriptions of FLUKA models 
and extensive benchmarking can be found in the literature (a 
collection of references can be obtained through the website, 
www.fluka.org).
Physics models of superior quality have extended the use of 
FLUKA to medical applications. Apart from physics, FLUKA 
is one of the first general-purpose MC codes, which translates 
DICOM files into voxel geometry as part of the combinatorial 
geometry package of FLUKA (10, 11). Recent developments in 
the user interface [Flair (12, 13)] further expanded the user-base 
of FLUKA. Features well received by users include the high-level 
management of the entire simulation process, including geometry 
generation (supported by interactive editing and versatile display) 
and material assignment (supported by built-in libraries, which 
include ICRU and ICRP tissue compositions). Additional func-
tionalities include semi-automated generation of PET  scanners 
and semi-automated recording of coincident events.
In Section 2, we shall review the status of ionization/multiple 
scattering models in FLUKA, together with the tools for biological 
dose simulations. The status of proton and ion nuclear interaction 
models, including fragmentation, will be reviewed, supported by 
examples of particle production with benchmarks. Section 3 will 
be dedicated to the application of FLUKA to the techniques for 
in  vivo monitoring of hadron therapy. A detailed presentation 
of the Flair interface in the context of radiation therapy can be 
found in Section 4. Finally, a review of the current application of 
FLUKA in two centers for hadrontherapy (CNAO and HIT) will 
be presented in Section 5.
2. DOse anD BiOlOgical DOse
2.1. charged Particle interactions 
in Matter
The most important atomic processes undergone by charged 
particles when traversing media consist of Coulomb scattering 
with both atomic electrons and nuclei. The effect of this same 
basic process is very different for electrons and nuclei because of 
their difference in mass. Inelastic interactions with atomic elec-
trons are by far the dominant source of charged particle energy 
losses (also referred to as electronic stopping power), while they 
give a contribution proportional to the atomic number Z to 
angular deflections. Elastic collisions with atomic nuclei result in 
negligible energy losses – usually referred to as nuclear stopping 
power  –  but the angular deflection is proportional to Z2. As a 
consequence, angular deflections are associated mostly with scat-
tering on atomic nuclei, but for the lightest elements where the 
two contributions become comparable.
Energy losses of charged particles are commonly expressed as 
an average energy loss per unit path length. The slowing down 
of energetic protons and ions in matter is governed by collisions 
with the atomic electrons and leads to the characteristic shape of 
the depth–dose profile of heavy charged particles with a peaking 
energy deposition, the so-called Bragg peak.
The nuclear stopping power contribution to the total energy 
loss of protons and ions in the energy range of relevance for 
therapy is negligible and will not be discussed further.
The implementation of the electromagnetic physics models 
in FLUKA, which describe continuous energy losses of heavy 
charged particles, energy loss straggling, delta-ray production, 
and multiple Coulomb scattering, is briefly described in the 
following.
2.2. electronic stopping Power
Electronic stopping powers are computed by FLUKA starting 
from the Bethe–Bloch (14–16) formalism. Several corrections to 
the standard formulation have been implemented in FLUKA in 
the recent years, allowing to obtain the high precision requested 
for the transport of therapeutic beams. The implementation 
follows, with modifications, extensions and refinements, the 
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functional forms presented in Ref. (17), complemented by Ziegler 
(18–20) at the lowest energies.
The formula for the average energy loss of particles much 
heavier than electrons and with charge z can be expressed by:
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for spin 0 particles and similarly for spin 1/2 particles. β is the 
projectile velocity relative to the speed of light, ne is the target 
material electron density ( ne
N Z
A
Av= ρ  for an element), I its mean 
excitation energy, M is the projectile mass, and γ
β
=
−
1
1 2  and Tmax 
is the maximum energy transfer to a stationary electron, which is 
dictated by kinematics and given by:
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Contrary to common approximations, all terms in equation (2) 
are kept in the FLUKA formulation. The “mean exitation energy” 
I is a sort of logarithmic average over all ionization and excitation 
levels of the target material. FLUKA uses for I the values recom-
mended in Ref. (17); however, the user can override them if new 
experimental data so suggest, as it is the case for water.
The terms δ, C/Z, L1, L2, and KM are all corrections to the 
Bethe–Bloch formalism. δ is the so called “density correction,” 
extensively discussed in the literature, and connected with 
medium polarization which, in FLUKA, is computed according 
to (21). C is the shell correction, which takes into account the 
effect of atomic bonds. This correction becomes important at low 
energies and, in FLUKA, it is extracted from the proton stopping 
power values reported in Ref. (17, 22) once all other corrections 
are undone. zeff is the projectile “effective charge,” which takes into 
account the partial neutralization of the projectile charge when 
its velocity is not much larger than those of the atomic electrons. 
For sufficiently large velocities, or for very light ions (e.g., protons 
and alphas) zeff = z, otherwise FLUKA makes use of the effective 
charge parametrizations proposed in Ref. (23); however, with 
different parameters in order to disentangle the effect of the L1, 
L2, and KM corrections, which were not considered in the original 
paper.
The code takes into account the z3, Barkas (24), and z4, Bloch 
(25), corrections (indicated by L1 and L2) to the first Born approxi-
mation according to the formalisms presented in Ref. (17, 26, 
27). A further correction KM, which is not commonly included in 
stopping power calculations but which turns out to be important 
for medium-heavy projectiles, is associated with the electron-ion 
Mott cross section (28). The Bethe–Bloch equation is based on 
the electron-ion scattering cross sections computed in first Born 
approximation; however, when the zα < < 1 (α is the fine structure 
constant) condition does no longer hold higher order corrections 
must be applied. The Mott cross section includes those correc-
tions; however, it is mathematically and computationally very 
complex. In FLUKA, the Mott cross section parameterization 
proposed in Ref. (29) as further modified in Ref. (30) are used to 
compute the correction to the average stopping power, as well as 
the associated corrections to the secondary electron production 
cross section and to the energy loss fluctuations.
For protons and alphas, the resulting unrestricted electronic 
stopping power values are fully consistent by construction to 
those available at Ref. (22, 31) as long as I is left unchanged. The 
FLUKA formalism has been demonstrated to be able to repro-
duce with high accuracy, and with a unique value of I for a given 
target, experimental data at energies up to several hundreds of 
MeV/n for ions ranging from protons to uranium, as shown in 
Section 2.6.
2.3. secondary electrons and energy 
loss Fluctuations
Fluctuations associated with charged particle energy losses are an 
important topic since they determine the shape and position of 
the Bragg peak. Indeed, its location does not correspond to the 
nominal particle energy but is situated slightly in front. The classi-
cal approaches to this problem, the Landau (32) and Vavilov (33) 
distributions, suffer from several limitations and are of difficult 
application in Monte Carlo codes (see Ref. (34) for a discussion).
An alternative approach (34) has been devised for FLUKA, 
which exploits the properties of the cumulants (35) of distribu-
tions. The approach can account for an arbitrary threshold for the 
explicit production of secondary electrons (“δ” rays), for arbitrary 
step-lengths, and for the contribution of distant collisions to 
energy loss fluctuations, while assuring the exact match of the 
average restricted stopping power. It also includes the effect of the 
Mott correction on energy loss fluctuations.
The explicit production and transport of secondary electrons 
can be described in FLUKA with a user defined threshold as low 
as 1 keV.
2.4. Multiple coulomb scattering
An extended model for charged particle transport through the 
multiple scattering formalism based on the Molière Theory 
(36–38) has been specially developed for FLUKA (39, 40).
It can be applied from very small to relatively large steps with 
a remarkable insensitivity of the resulting distributions. It is com-
plemented by the possibility of switching to single Coulomb scat-
terings, a possibility which was first proposed and implemented 
in FLUKA.
Examples of the performances of this model when applied to 
therapy beams and energies can be found in Ref. (41).
2.5. nuclear interaction Models
As a consequence of nuclear reactions, the intensity of therapeu-
tic hadron beams is attenuated all along the propagation in tissue. 
It follows that the dose delivered by primary ions is reduced 
with increasing depth. While nuclear recoils result typically in 
negligible spatial modifications of the delivered dose, secondary 
nucleons, particles, and fragments produced in nuclear reactions 
FigUre 1 | Double differential neutron production for 135 MeV/n 12c 
interactions in a thin carbon target. FLUKA–RQMD predictions as a 
function of neutron energy at several detection angles are shown as 
histrograms and compared with experimental data (dots) from Ref. (57).
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can considerably affect the spatial pattern of energy deposition 
and must be carefully taken into account. For proton beams, only 
target fragmentation is possible. For heavier ions, projectile frag-
mentation is the most important process leading to the build-up 
of secondary particles along the penetration depth. Because of the 
reaction kinematics, projectile fragments travel nearly in forward 
direction at almost the same velocity as the incident particle. The 
secondary lower-charge fragments have typically a longer range 
than the primary beam and give rise to an undesirable dose 
deposition beyond the Bragg peak. Furthermore, the fragments 
angular emission can contribute to an additional lateral spread of 
the beam particularly evident at the distal side of the Bragg peak, 
where the primary projectiles are stopped and the dose deposi-
tion is due to nuclear fragments only. Hence, in the case of heavy 
ions, nuclear fragmentation reactions are responsible for the 
deterioration of the physical selectivity in the longitudinal and 
transversal dimension especially around the Bragg peak region. 
The amount of fragments produced generally increases with the 
mass and charge of the primary particle.
The FLUKA nuclear interaction model, called PEANUT 
(42–45), provides the nuclear environment for hadron, photon, 
muon, and neutrino interactions from a few MeV up to the 
energies, for instance, of the CERN Large Hadron Collider. At 
energies of interest for therapy, PEANUT models the interactions 
along the steps of a generalized intranuclear cascade (GINC), 
followed by an exciton based preequilibrium particle emission 
and by an equilibrium phase. Detailed descriptions of the “fast” 
reaction stages, as well as comparisons with particle emission 
data, can be found in the literature (42–46). A combined bench-
mark on nuclear interactions and electromagnetic interactions is 
described in Ref. (47). Produced nuclei form a thermally equili-
brated system, characterized by its excitation energy. This system 
can “evaporate” nucleons, or fragments, or γ rays, or even fission, 
to dissipate the residual excitation. Evaporation and fission in 
FLUKA are based on statistical approaches (42, 48).
For light residual nuclei (A < 16), where the excitation energy 
may overwhelm the total binding energy, a statistical fragmen-
tation (Fermi Break-up) model is implemented (49–51). The 
excitation energy still remaining after evaporation is dissipated 
via emission of γ-rays, as will be described in Section 3. Recently, 
competition of gamma ray emission with particle evaporation 
has also been implemented. As will be described in the follow-
ing sections, the low excitation stages of nuclear interactions are 
presently under strong development.
Reactions initiated by ions are dealt with by different event 
generators, depending on the projectile energy. The one related 
to the highest energies (10, 52, 53) is not of interest for therapy 
applications and will not be described here.
For ions in the few GeV/n energy range and down to 
≈0.1 GeV/n, FLUKA uses an interface to a modified version of 
RQMD-2.4 (54, 55). RQMD is a relativistic quantum molecular 
dynamics model that can also be run in intranuclear cascade 
mode. Examples of FLUKA results compared with experimental 
data when running with the modified RQMD-2.4 model can 
be found in Ref. (10, 56). Since RQMD provides only the fast 
stage of the reaction, excited fragments from RQMD are further 
processed by PEANUT. This allowed also to profit from all the 
improvements that are ongoing in PEANUT. In Figure  1, the 
neutrons emitted at en energy close to the projectile one are 
mainly caused by evaporation. The latest development in the 
RQMD interface is the inclusion of the preequilibrium stage 
in the treatment of residual fragments. This stage improves the 
distribution of high energy ejectiles, in particular for projectile 
energies in the sub-GeV/n region. An example of the latest 
performances of FLUKA +  RQMD is shown in Figure  1. The 
agreement is remarkable, especially because RQMD is used at an 
energy that is at its very limit of application.
The Boltzmann Master Equation [BME (58)] model has been 
implemented into FLUKA to deal with the lowest energies, below 
about 150 MeV/n (FLUKA switches gradually between RQMD 
and BME at threshold). The BME event generator (59) in FLUKA 
simulates thermalization of a composite nucleus, created in the 
complete or incomplete fusion of two ions, by sampling from the 
results of the numerical integration of the BMEs. While complete 
fusion covers the lowest impact parameter interval, for more 
peripheral collisions a three body picture of the reaction is imple-
mented. At even higher impact parameters, single nucleon mode 
break-up/transfer is modeled. Recently, the BME event generator 
has been interfaced with the PEANUT pre-equilibrium module 
in order to treat the first de-excitation stage of all nuclei for which 
FigUre 3 | FlUKa simulations of depth–dose profiles of protons and 
carbon ions with therapeutic ranges in comparison with measured 
data at hiT (61). The nominal energies before the beamline are 54.19, 
142.66, and 221.05 MeV/u forprotons, and 200.28, 299.94, and 
430.10 MeV/u for carbon ions.
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FigUre 2 | Double differential spectra of neutrons from 100 MeV/n 
alphas on a thick carbon target, scaled as indicated at the different 
angles with respect to the beam direction. Full circles are experimental 
data (60), histograms with empty symbols are FLUKA predictions.
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BME information is not (yet) available. This development is par-
ticularly important, for instance, for reactions induced by alpha 
particles, as shown in Figure 2, where double differential neutron 
production by a 100 MeV/n 4He beam impinging on a thick car-
bon target is compared to measurements. As for RQMD, the final 
de-excitation of the remaining equilibrated nucleus is handled by 
the FLUKA evaporation/fission/fragmentation module.
2.6. comparisons with Depth–Dose 
curves and lateral-Dose Profiles
FLUKA has been intensively benchmarked against depth–dose 
data and lateral-dose profiles from various accelerators used for 
research and clinical ion-beam therapy (IBT), which have been 
typically acquired with different water columns with parallel-
plate ionization chambers [depth–dose (61, 62)] and small vol-
ume ionization chambers in water [lateral-dose profiles (63)]. 
As a consequence of its performances, it is used at IBT centers 
for independent dose verification in phantom and patient geom-
etries (see Section 5) as well as to generate basic physics input 
data for clinical treatment planning systems tailored to proton 
and carbon ion delivery with modern beam scanning (64). These 
latter TPS basic data include MC-calculated laterally integrated 
depth–dose distributions, depth–dependent parameters of lateral 
Gaussian distributions fitted on the MC lateral-dose profiles, and 
MC-generated carbon ion fragment spectra for biological calcu-
lations (41, 61, 62, 65, 66). Recently, FLUKA has also been chosen 
by a commercial vendor as a validation tool and to provide phys-
ics input data for their newly developed carbon ion module (67).
Figure 3 shows exemplary depth–dose profiles simulated by 
FLUKA for proton and carbon ions in the therapeutic energy 
range, compared to measurements taken at the Heidelberg ion 
therapy center (HIT) with the PeakFinder water column (PTW 
Freiburg) (61). The nominal energies before the beamline for the 
presented ions are 54.19, 142.66, and 221.05 MeV/u for protons, 
and 200.28, 299.94, and 430.10  MeV/u for carbon ions. Since 
nuclear processes determine notably the shape of the depth–dose 
profiles, especially for carbon ion and high energy proton beams, 
these comparisons are not only a sensitive benchmark for the 
electromagnetic physics models but represent, at the same time, 
an integral benchmark for the nuclear models in their capabili-
ties of predicting non-elastic nuclear interactions. For different 
high-accuracy data sets, FLUKA is able to reproduce the posi-
tion of the Bragg peaks of proton and carbon ion beams with 
a single ionization potential on average within the experimental 
uncertainties of about 100 μm. The average dose-weighted dose-
difference ( )∆ /D D  is below 1% for protons and below 1.5% for 
carbon ions.
An extensive experimental characterization of the other ions 
available at HIT in comparison to FLUKA simulations is also 
being performed. A first in-depth characterization of depth–dose 
profiles of oxygen ion beams has been presented in Ref. (68), 
and several investigations with helium ion beams are ongoing 
for both mono-energetic and spread-out Bragg peaks. Figure 4 
shows the comparisons between depth–dose profiles acquired 
with the above mentioned PeakFinder and FLUKA simulations 
for the different ions available at HIT and different initial beam 
energies spanning the whole therapeutic range. The nominal 
energies before the beamline for the displayed ions are 54.19, 
79.78, 200.28, and 300.13 MeV/u, for protons, helium, carbon, 
and oxygen ions, respectively. Quantitative assessment of the 
level of agreement between measured and simulated depth–dose 
distributions of these ions has been determined by calculating 
the weighted chi-square difference for irradiation of an energy 
yielding the same range (ca. 15 cm in water) without ripple filter, 
as proposed in Ref. (68). The smaller the weighted chi-square dif-
ference is, the higher the similarity is between measurements and 
simulations. The results indicate for the clinically used protons 
and carbon ions a level of chi-square agreement of 5.8 ×  10–5 
and 1.1 × 10–4, respectively. Compared to this reference level, the 
helium ions exhibit promising weighted chi-square differences of 
FigUre 4 | FlUKa simulations of depth–dose profiles of protons, 
helium, carbon, and oxygen ions with therapeutic ranges in 
comparison with measured data at hiT. The nominal energies before the 
beamline are 54.19, 79.78, 200.28, and 300.13 MeV/u, for protons, helium, 
carbon, and oxygen ions, respectively.
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2.1 × 10–4 and oxygen ions 5.6 × 10–5. Additionally, the average 
dose-weighted dose-difference was evaluated, again for the same 
energies chosen to provide the same range, and found to be 0.6% 
for protons, 1.6% for helium ions, 0.8% for carbon ions, and 1.3% 
for oxygen ions. Again, range agreement within 110 μm could 
be obtained for both He and O ions over the entire therapeutic 
energy range with a single ionization potential value in water. 
Compared to the extensively validated and already clinically 
used protons and carbon ions, the overall agreement observed 
for helium and oxygen ions is encouraging, but room for Monte 
Carlo model improvements is still possible, especially if more 
experimental data will become available in the therapeutic energy 
range and for materials of clinical relevance.
In terms of lateral-dose profiles, Figure 5 shows an example 
of agreement between FLUKA simulations, including the detailed 
modeling of the HIT beamline according to Ref. (41), and meas-
urements for protons (nominal energy of 157.43 MeV/u before 
the beamline) and carbon ions (nominal energy of 299.94 MeV/u 
before the beamline), sampled at two different depths in water in 
the entrance region, at approximately 16 mm, and shortly before 
the Bragg peak, at approximately 152 mm. Taking into account 
unavoidable uncertainties of the measured data in the low-dose 
region, as well as averaging volume effects of the small cylindri-
cal ionization chambers of 1.5 mm radius in comparison to the 
dose gradient (63), the agreement is quite satisfactory. A more 
extensive quantitative comparison of FLUKA simulations and 
experimental lateral dose-data collected at different energies and 
depths can be found in Ref. (69).
2.7. Biological calculations
A major rationale for the application of ion beams in tumor 
therapy is their increased relative biological effectiveness (RBE) 
in the Bragg peak region, especially for carbon and heavier ions. 
For dose prescription in carbon ion therapy, the increased effec-
tiveness has to be taken into account in treatment planning while, 
in proton therapy, a constant RBE of 1.1 is typically applied as 
recommended by ICRU (70).
In order to describe the biological effect with FLUKA, an exter-
nal radiobiological database has to be integrated. The database can 
be obtained from experimental data or starting from event-by-
event track structure simulations. This approach was adopted in 
the past to characterize therapeutic proton beams from a physical 
and biophysical point of view (71, 72). Afterward, the approach 
has been used in the study of chromosome aberration induction 
in human cells by neutrons (73). The theory of dual radiation 
action [TDRA (74)] has been included to describe the non-linear 
response due to mixed fields, and it has been the basis of more 
recent calculations interfacing FLUKA with the biophysical model 
LEM [Local Effect Model (75)], which allows prediction of RBE 
and RBE-weighted dose (DRBE) distributions in carbon ion beam 
therapy (4, 66). Starting from these promising works, we decided 
to develop a general interface within the linear-quadratic formal-
ism (76) available in FLUKA. The users should provide their own 
biological database in terms of α and β of different components of 
the mixed radiation field as a function of energy per nucleon. In 
order to compute the biological effect, FLUKA applies an approach 
based on the dose-weighted averages jα  and jβ :
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where Δdi,j is the dose from the i-th charged particle (composing 
the mixed radiation field) with associated αi,j and βi,j in voxel j, 
and i runs over all particles depositing dose in voxel j. RBE and 
RBE-weighted dose values can be determined for each voxel of 
the patient knowing the absorbed dose and the dose  weighted 
ave ages jα  and jβ  [e.g., see Ref. (4)]. As an example in Figure 6, 
the α  and β  (left panel) and the absorbed dose and DRBE (right 
panel) for a carbon ions biologically optimized Spread-Out Bragg 
peak as available at CNAO are reported. A single-field irradiation 
plan has been optimized with the CNAO TPS (SIEMENS syngo® 
PT Treatment) to achieve a homogeneous dose distribution of 
3 Gy (RBE) in a cubic shaped target (side = 6 cm) centered at 9 cm 
depth in water. The FLUKA recalculations have been performed 
for a representative cell line characterized by (α/β)ph  =  2  Gy 
(αph =  0.1  Gy–1 and βph =  0.05  Gy–2) using the same biological 
database as implemented in the TPS (75). This database is 
calculated using the radio-biological model LEM I (75), which 
has been in  vitro and in  vivo validated. LEM I is the standard 
biological model employed at the carbon ion therapy facilities in 
Europe and has has been developed and benchmarked by the GSI 
biophysics group.
3. IN VIVO VeriFicaTiOn
3.1. introduction
The inverse depth–dose deposition profiles of high energetic pro-
ton and ion beams can be used to obtain highly conformal dose 
FigUre 5 | FlUKa simulations of lateral-dose profiles of protons (top) and carbon ions (bottom) in water, with a nominal initial energy before the 
beamline of 157.43 and 299.94 MeV/u, respectively, sampled in the entrance region (left) and shortly before the Bragg peak (right), in comparison to 
experimental measurements taken at hiT.
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distributions for therapeutic purposes. However advantageous, it 
is then crucial to ensure treatments are delivered with high preci-
sion, according to the planner’s prescription. Techniques, which 
aim to verify the patient geometry as well as the correct treatment 
delivery before, during, or directly after treatment, have therefore 
been increasingly investigated in recent years in literature. In vivo 
range monitoring via β+-emitter distributions by PET is currently 
the most advanced monitoring technique routinely used in clini-
cal environments. Simulation studies indicated the feasibility to 
detect range misses in the order of 6 mm and larger (77), and even 
better results were reported for favorable anatomical indications 
in multiple clinical pilot studies with different PET implementa-
tions (3, 78–81).
While results achieved with this technique are promising, 
widespread clinical use of PET monitoring is presently still 
hampered by several issues. The coincidence measurements of 
511 keV annihilation photons allow reconstruction of β+-emitter 
maps, which have a complex correlation with the delivered dose. 
Hence, only a limited correlation between signal on the one hand, 
and dose and beam range on the other hand, can be achieved. 
Besides, an extended acquisition time (of the minute-scale) 
is needed because of the low β+ activity and relatively small 
signal-to-noise ratio (SNR) (6). Furthermore, an additional 
signal attenuation is due to the long delay before starting acqui-
sition after patient irradiation. This delay, of the order of a few 
minutes, appears in the commonly used in-room or off-line PET 
monitoring method. Finally, metabolic washout, PET and CT 
co-registration, and possible patient movements lead to a further 
decrease of the resolution (79).
The use of prompt-γ’s for monitoring was proposed to over-
come some of the inherent limitations of the PET technique. 
Besides a possibly larger signal strength compared to PET 
FigUre 6 | left panel: a  (solid line) and b  (dashed line) mixed radiation field values calculated as a function of depth in water. The β  results have 
been rescaled by a factor of ten for display purposes. Right panel: absorbed dose (dashed line) and DRBE (solid line) values calculated as a function of depth in water.
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resulting in a larger SNR, this method allows in a straightforward 
way for  real-time monitoring and might provide a better correla-
tion of the prompt-γ signal with dose and beam particle ranges 
(82). These potential advantages have yet to be demonstrated in a 
clinical setting. For such purposes, large efforts have been spent 
in the design and optimization of detection devices and setups 
suitable for use in clinics (83–91). Research in this field is still 
ongoing, as well as feasibility and sensitivity studies aiming at 
revealing the expected performance and limitations of prompt-γ 
range and dose monitoring (82, 92–95). Monte Carlo (MC) par-
ticle transport codes, such as FLUKA (9, 50) are essential tools 
for such studies.
Using these simulation tools for the above-mentioned 
applications, implicitly relies on their predictive power, i.e., the 
accurate description of a range of physics processes relevant to 
the problem. Dose distribution predictions with MC codes were 
shown to largely satisfy clinical needs in proton and carbon ion 
treatment planning a given geometry (61, 96). On the other 
hand, the development and validation of MC codes for prompt-γ 
production is significantly less advanced. This is partly due to the 
large complexity of non-elastic nuclear reactions.
Some recent studies have been aimed at elucidating and 
comparing the predictive capability for prompt-γ production of 
proton and ion beams of some MC and nuclear reaction codes 
(95, 97–99). Independently from the general agreement about 
the scarcity of available experimental data, various modeling 
approaches and measurements have been reported to differ by 
a factor of 2 to 12 in prompt-γ emissions. In particular, dif-
ferences in the predictions of the distal fall-off positions up 
to a few millimeters as well as remarkable discrepancies in 
the relative shapes of the prompt-γ profiles are noted. These 
findings clearly highlight the need for further development 
and validation of physics models in order to predict prompt-γ 
yields of high energy ion beams, based on a solid measurement 
database.
This section presents a set of physics models describing 
prompt-γ-emission and β-emitter production as a result of 
non-elastic nuclear collisions of proton and ion beams. Newly 
developed and refined models are described, which account 
for discrete and continuous components of γ emission spectra 
including Doppler effect.
The performance of the models for applications to imaging is 
evaluated using cross section and thick target data.
3.2. FlUKa Model Developments for 
In Vivo Verification
The accuracy of physics models included in particle transport 
codes is of great relevance, especially as their importance in par-
ticle therapy has steadily increased over the last years (5). Both β+ 
emitters and prompt γ production occur in the very last stage of 
nuclear interactions, therefore they are sensitive to the details of 
all the reaction “history.”
The relative production probabilities of different residual 
nuclei are influenced by the exact amount of excitation energy 
left in the system, by the exact balance of binding energy, but 
also, and this is more difficult to simulate, by the level structure 
of the excited and residual nuclei. Not only the level energies but 
also spin and parity have an influence on isotope production 
and photon emission. This is particularly true in the Bragg peak 
region, where the available projectile energy is barely sufficient to 
initiate the reaction. Low energy nuclear models in FLUKA have 
undergone a steady development with a particular attention to 
processes of interest for hadron therapy.
The most important reactions for PET monitoring of proton 
therapy are 16O(p,x)15O and 12C(p,x)11C (98). They can proceed 
through emission of either independent nucleons or deuterons. 
The emission of composite ejectiles, like d, t, 3He, and α, is described 
in FLUKA by the coalescence algorithm in the first stages of the 
reaction, and by evaporation of fragments in the equilibrium 
stages. Coalescence is a postemission process, meaning that all 
combinations of unbound nucleons are checked and the possible 
formation of light fragments (up to mass 10) is decided based 
on phase space closeness at the nucleus periphery. This approach 
works reasonably well at medium/high energies. However, at 
energies below a few tens of MeV, where binding energies play a 
crucial role, coalescence is increasingly ineffective in reproduc-
ing the data. Recently, a direct deuteron formation mechanism, 
where the deuteron is formed before being emitted, has been 
TaBle 1 | isotope production cross sections (in millibar) for the 
fragmentation of 86 MeV/n 12c ion projectiles on a carbon target.
isotope exp. FlUKa (%) 
11C 43 54 ± 1
10C 4 2 ± 7
11B 42 54 ± 1
10B 28 25 ± 2
8B 2.4 3 ± 6
Data (104, 105) are compared to FLUKA predictions, integrated over the measured 
angular range from 2° to 22°. The experimental uncertainty is on the order of 10% 
(106).
FigUre 7 | FlUKa predictions for the reactions nat,12c(p,x)11c and 
nat,16O(p,x) 15O cross sections as a function of projectile energy, 
compared against data retrieved from the eXFOr library (101).
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implemented in FLUKA. This mechanism greatly improved the 
predictive power for reactions, such as (p,d). An example outlin-
ing the effectiveness of the new approach and directly relevant 
for proton therapy monitoring with PET is given in Figure 7. The 
level of accuracy reached allows to overcome the previously stated 
need (100) to convolute simulated fluxes with cross section data.
An interesting verification of FLUKA predictions against 
experimental data taken with a prototype PET system can be 
found in Ref. (102). For what concerns ion beams, the avail-
ability of experimental data on β+ emitter is scarce, more would 
be needed to perform a careful evaluation of model predictions. 
However, the results presented in Table  1 on carbon–carbon 
interactions at low energy show a reasonable agreement, within 
25%, for the production of 11C. Indeed, the early work described 
in Ref. (103) already showed a satisfactory agreement between 
data and simulations on a full phantom and PET setup.
Finally, it has to be reminded that electromagnetic models 
can also play a role in the reproduction of PET reality. A cor-
rect reproduction of positron slowing down before annihilation 
is of course mandatory, but FLUKA goes further in precision 
and includes an accurate reproduction of the effects of electron 
binding energy and orbital motion on the emitted photon pair. 
The resulting acollinearity of the photon pair has been favorably 
compared with experimental data in Ref. (107).
At the end of the nuclear evaporation stage, the PEANUT 
model dissipates the residual excitation energy through emission 
of cascades of γ rays. Whenever possible, photon energies and 
branching ratios are sampled according to a database of known 
levels and transitions, derived from the most recent release of 
the RIPL (108) data provided by IAEA. The evaporation stage is 
also constrained to proceed through known levels when they are 
available. A first attempt to account for the angular distribution of 
emitted photons has been implemented, following the formalism 
in Ref. (109).
Whenever the level compilation is non-existent or incomplete, 
photon energies are sampled according to a statistical/rotational 
model that has been validated in the past (110).
The most stringent requirement for a model of prompt photon 
production is the capability to reproduce excitation functions 
of single γ lines. Those depend on the capability to reproduce 
both the branchings in the various reaction channels, and the 
γ de-excitation flow. Examples of such excitation functions for 
proton-induced reactions in carbon are shown in Figure 8, where 
FLUKA results compare favorably with experimental data (111).
3.3. Model comparison with integral 
Measurements
Complementary to single interaction data, which can give a direct 
evaluation of the model performances, the study of integrated data 
for therapeutically relevant scenarios allows an estimation of the 
model performance for specific applications, such as conceptual 
and detector design studies.
3.3.1. FLUKA Configuration and Modeling  
of the Setups
Several prompt-γ measurements using ion beams have been 
conducted in recent years with the purpose to characterize and 
quantify γ production for therapeutic scenarios. Table  2 lists 
prompt-γ measurements selected for comparison. They span dif-
fering experimental setups for proton and carbon ion beams at 
various therapeutic energies and include polymethyl methacrylate 
(PMMA) and water targets. In all considered experiments, the 
beam hits a homogeneous tissue-like target with the detectors 
positioned in a direction perpendicular to the beam axis.
Measured data include γ emission profiles with depth as well as 
photon energy spectra. For each experiment, the relevant meas-
urement configurations and main setup elements were modeled 
to scale for FLUKA simulations as specified by the experimental-
ists, including notably: beams, targets, collimators, and detectors 
(see Figure 9).
Neutrons were the major source of contamination in 
detectable counts. For noise rejection purposes, SII and SIII 
were both time gated and energy windowed, applying a 2 MeV 
low-energy threshold. These settings were reproduced for the 
simulations. Lead collimators were placed between the target 
TaBle 2 | Prompt-γ experiments selected for comparison with 
simulations.
setup Beam Target Detector Facility exp. 
reference 
SI 160 MeV 
proton 
PMMA NaI WPE, 
Essen
(112)
SII 95 MeV/u 12C PMMA BaF2 GANIL, 
Caen
(95)
SIII 310 MeV/u 12C Water BaF2 GSI, 
Darmstadt
(95)
FigUre 8 | excitation function for the emission of discrete γ lines from proton-induced reactions on carbon. Left: the 4.440 MeV line, corresponding to 
the de-excitation of the 1st excited level in 12C, the 2nd excited level in 11B, the 2nd excited level in 11C. Right: the 2.0 MeV line, from the 1st excited levels of 11C and 
11B. Curves are FLUKA predictions, dots are evaluated data from Ref. (111).
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and the detector, as shown in Figure 9. The reader is referred 
to the original references for further experimental details (see 
Table 2).
The measurement setup SI was repeated in three different 
configurations: (1) with no collimation device, (2) with a lead 
block, instead of the collimator, in front of the detector, and 
(3) with the collimator, as depicted in Figure  9. The dataset is 
presented as a background-subtracted photon spectrum in two 
manners. These difference spectra aim to obtain a larger gamma-
to-neutron signal ratio in the experimental data. The first one, 
termed “opening difference” in the following, is the difference 
of the spectra for the opened (3) and the closed (2) collimator 
configuration. The second one, termed “wall difference,” is the 
difference of the spectra acquired for the no-collimator (1) and 
the closed-collimator (2) configuration. The geometry shown in 
Figure  9 (left) is for a target-to-detector distance of 50  cm. A 
separate dataset for target-to-detector distance 100 cm was also 
acquired (112). The detector, a NaI crystal, was determined to 
have a resolution of 7% full width at half maximum (FWHM) at 
662 keV (112). The simulated energy spectra were therefore con-
voluted with the Gaussian distribution reflecting the measured 
detector resolution.
Certain experimental details, which are not accounted for by 
the simulations, may have an effect on the experimental data, 
causing artifacts. These potentially include ghosting from preced-
ing beam pulses as well as geometry, setup, and reconstruction 
details, which are not reproduced by the simulations.
3.3.2. Prompt-Gamma Energy Spectra
Simulations of photon spectra resulting from proton beams are 
presented in Figure  10 in comparison with measurements for 
setup SI with and without accounting for the intrinsic detector 
resolution. Data are presented as background-subtracted photon 
spectra for the configurations “opening difference” and “wall 
difference.” Measured and simulated spectra are normalized to 
the number of primary protons and the energy bin, originally 
9.83 keV.
Overall, the agreement between simulated spectra and experi-
mental data is excellent. In particular, an agreement within about 
10% is found for the “opening difference”-spectra. For the “wall 
difference”-spectra (difference between closed-collimator and 
no-collimator configurations), the accuracy of the simulation is 
also favorable, achieving an agreement within 10% for energies 
beyond 2  MeV. The result is remarkable, considering that the 
“wall difference” configuration is more sensitive to measurement 
artifacts not accounted for by the simulation, such as activa-
tion produced by previous beam pulses, pile-up of low energy 
particles, and scatter-radiation from the nozzle, which is partly 
screened by the collimator.
3.3.3. Integral Prompt-Gamma Yields  
as a Function of Depth
The validation of the code in depth profile experiments is essential 
for prompt-γ studies. Figure 11 shows simulations and measure-
ments of photon-depth profiles resulting from carbon beams 
for setup SII and SIII. Note that the measured data, previously 
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FigUre 10 | Background-subtracted photon energy spectra for setup si with target-detector distances of 50 cm (left) and 100 cm (right) are shown 
for the “opening difference” (top) and the “wall difference” (bottom). Simulated spectra with and without intrinsic detector resolution are presented in 
comparison with measured data (112).
FigUre 9 | simulated configurations of targets (T), collimators (c), and detectors (D) for si (left), sii (middle), and siii (right), each drawn to scale. The 
beam impinges perpendicularly on the center of the target face marked with a ‘T’.
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reported in Ref. (95), have recently been revised by the authors, 
providing a new absolute normalization (113, 114) and revision 
of the systematic uncertainties. Hence, updated experimental 
data are presented in Figure  11. The initial experimental data 
points, measured at −2 and −4 cm for setup SII and −1.5 cm for 
setup SIII, are taken at depths before the start of the phantoms. 
Only a very small photon yield in air is expected for these posi-
tions. The measured signals for these depths can therefore be 
assumed to represent mostly measurement background. Hence, 
a background subtraction using the revised data of 6.3 × 10–7 (SII) 
and 4.0 ×  10–7 (SIII) counts/primary ion has been additionally 
performed, in order to obtain measured photon yields close to 
zero for measured data points before the start of the phantoms. 
A smearing due to detector resolution has been applied to simu-
lated data. For the measured data points, vertical bars indicate 
the systematic uncertainties as reported in the original papers. 
For the simulated data points, vertical bars indicate the statistical 
uncertainty.
By introducing the corrections discussed above, the compari-
sons show not only a satisfactory agreement in the relative shapes 
of the profiles but also a good absolute agreement for setups. 
These findings are consistent with the expected agreement from 
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FigUre 11 | integral photon yield as a function of depth. Simulated (blue circles) and measured [red asterisks (95, 114)] data are shown for carbon ion beams 
for setup SII (left, 95 MeV/n on PMMA, the original experimental data have been re-evaluated in 2012) and SIII (right, 310 MeV/n on water). Simulated depth–dose 
distributions are also shown as green lines with arbitrary normalization.
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the comparisons of the prompt-γ energy spectra in the previous 
section.
4. Flair anD iTs aPPlicaTiOns TO 
raDiaTiOn TheraPY
4.1. introduction
Flair (12, 13) (Figure  12) is a user-friendly graphical interface 
for the FLUKA (8, 9, 50) Monte Carlo transport code. It provides 
an Integrated Development Environment (IDE) for all stages of 
FLUKA simulations, from building an error free input file, to 
debugging, creation of user written routines, execution, status 
monitoring, data processing, and plot generation. The program 
employs a custom 2D/3D fully functional graphical editor (13) 
and debugger for building geometries.
The graphics editor provides very fast graphics with real-
time 3D ray-traced rendering of complex geometries as well a 
dynamic layer mechanism allowing the user to fully custom-
ize and create sophisticated views overlaid on the geometry. 
The use of the program greatly enhances the productivity of 
the users and provides much steeper learning curve for the 
beginners. Thanks to the modular design of Flair, recently it 
was enhanced with the possibility to import, display, process, 
and convert DICOM files to FLUKA compatible input, as well 
as with an automatic PET geometry generator. The geometry 
generator eases the construction of a PET detector with general 
parameters. The user can also benefit from multiple templates 
of commercial PET scanners provided within the interface. 
This section describes the current state of implementation of 
the medical tools already functional inside Flair as well the 
future plans. The program and the source code can be freely 
downloaded from Ref. (115).
4.1.1. DICOM Description
Digital Imaging and Communications in Medicine (DICOM) 
(116) is a standard for handling, storing, printing, and transmit-
ting information in medical imaging. DICOM supports a wide 
range of medical images across the fields of radiology, cardiology, 
pathology, and dentistry. The format is quite versatile and can 
host practically any kind of information.
Depending on the modality type of each file, a different class 
has been implemented in Flair to cope with it. Presently, Flair is 
able to handle the following modalities:
•	 CT – Computed tomography, represented with multiple files 
each containing a 2D sliced Z image.
•	 MR  –  Magnetic resonance imaging, with all the necessary 
information in a single (or multiple files) containing a 3D 
representation.
•	 RTDOSE – Radiotherapy dose distribution.
•	 RTPLAN – Radiotherapy treatment plan.
•	 RTSTRUCT  –  Radiotherapy structure set, describing 
structures/objects.
4.2. DicOM Processing in Flair
Flair is using pydicom (117), an open source package for reading 
and writing DICOM files using the python programing language, 
and the numerical python – NumPy (118) libraries for process-
ing the DICOM files. Pydicom can read and write all standard 
DICOM files, including nested sequences such as found in 
DICOM RT files or in structured reports.
The user is able to inspect selected DICOM files either graphi-
cally from the Flair DICOM slice viewer or from the enhanced 
tree structure text browser (Figure 13). The slice viewer is capable 
of displaying the 2D slices from the DICOM for the CT, MR, 
RTDOSE, and RTSTRUCT modalities and allows the user to 
FigUre 12 | Flair graphical interface (left), graphical geometry editor (right).
FigUre 13 | Flair dicom viewer, with rTsTrUcT superimposed (left); DicOM tree browser (right).
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perform simple operations on the slices (like cropping, rescaling, 
etc.). For RTSTRUCT files, the structures are overlaid on the cor-
responding display of the CT/MRI slices.
Recent development effort was put on providing a better visu-
alization and comparison between TPS and FLUKA re-calculated 
dose values. The new RTViewer (Figure  14) is able to present 
2D cross-sectional CT images for axial, coronal, and sagittal 
planes combined with the RTDOSE and FLUKA calculations 
results. It also supports the user with visualization of the differ-
ences between MC calculated dose values and TPS prescription. 
Current development is focused on displaying MR scans, merg-
ing three planes with the overlaying ROIs defined in RTSTRUCT, 
and providing the user with referenced DVH plots.
4.2.1. DICOM to Voxel Conversion
The CT scans contain integer values (so-called Hounsfield Units) 
reflecting the X-ray attenuation coefficient μx as a linear transfor-
mation of the original attenuation coefficient relative to the one 
from distilled water at standard temperature and pressure (STP) 
conditions:
 HUx x H H air= − / −1000 20 20( ) ( )µ µ µ µ  (4)
typically in the range of −1000 ≤ HU ≤ 3500.
Air has typically a HU of −1000, which is the lowest HU value 
in the file. In FLUKA, we loosely use the word organ to indicate 
a group of voxels (or even more than one group) made of the 
FigUre 14 | new DicOM Viewer interface. Coronal CT plane with mapped physical dose [Gy] from RTDOSE and FLUKA calculation. On the right differences 
between obtained values [Gy].
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same tissue material (same HU value or in a given HU interval). 
Internally, FLUKA will handle each organ as a constructive solid 
geometry region, possibly in addition to other conventional non-
voxel regions defined by the user.
Assigning a separate material to each of the ~3000–5000 HU 
values, typically present in a CT, is neither memory- nor CPU-
efficient for simulations. Therefore, ranges of HU are grouped 
into organs while providing a mechanism to allow a continuous 
HU-dependent scaling of interaction properties of the materials. 
Flair includes the Schneider (1) parametrization, which segments 
the CT into 24 materials of defined elemental composition based 
on the analysis of 71 human CT scans, and assigns to each mate-
rial a nominal mean density, e.g., using the density at the center 
of each HU interval (1, 119, 120).
Real density (and related physical quantities) varies continu-
ously with HU value, therefore in FLUKA, we split the 24 material 
description in smaller intervals (41 intervals in total), and we 
apply a scaling correction. Specific ranges of HU values share the 
same material and during transport an additional scaling factor 
is applied on the density for the nuclear and for the electronic 
processes, based on the real HU value. To accommodate for this 
change, the FLUKA voxel format was enhanced to include the 
possibility to embed FLUKA input cards that contain all the infor-
mation on the materials, assignments, and correction factors.
4.2.2. Radiotherapy Treatment Information
As already mentioned, Flair is now capable of importing also the 
radiotherapy treatment data described in the dedicated DICOM 
RT (RTSTRUCT, RTDOSE, RTPLAN) standard.
4.2.2.1. RTSTRUCT
The radiotherapy structure set object of the DICOM standard 
is used for the transfer of patient structures and related data, 
between the devices found within and outside the radio-
therapy department. It contains mainly the information for 
regions of interest (ROIs) and points of interest (e.g., dose 
reference points). The ROIs can be used during the simulation 
for calculating Dose Volume Histograms (DVH) or perform 
special scoring on an organ basis. The ROIs are represented 
as the points belonging to a closed polygon using 2D coor-
dinates (not rounded to the pixel size of the corresponding 
CT image).
When selecting an RTSTRUCT file to be embedded into 
the VOXEL file, Flair will identify for each voxel to which 
ROIs it belongs. The case of voxels belonging to more than one 
ROI is also taken into account. A matrix containing the voxel 
to ROI correspondence is included in the VOXEL file read 
by FLUKA. This additional matrix is used by Flair for plotting 
purposes and/or by FLUKA for scoring and DVH calculations 
(Figure 13).
Flair provides some checks on the structures like calculating 
volumes using the true polygonal information or the discretiza-
tion to voxels. Typical differences up to a few percent can be 
noticed induced by the quantization process.
4.2.2.2. RTDOSE
The RTDOSE can be converted to a FLUKA USRBIN, a 3D mesh 
tally. This is possible for all modalities having a PixelData tag like 
CT, MR, and RTDOSE. Once converted, it can be further used 
for plotting and comparing the results, e.g., from the output of 
a treatment planning system with a FLUKA simulation. In the 
RTViewer (Figure 14), the user can import the chosen sequence 
dose data or compare the entire treatment fraction and visualize it 
mapped on the CT scans. USRBIN can be also used as a primary 
source particles generator, e.g., the PET/CT dose description 
followed after an FDG (Figure 15).
FigUre 15 | DicOM to VOXel import of cT data together with the rTDOse superimposed. Displayed using the Flair geometry editor.
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4.2.2.3. RTPLAN
The RTPLAN contains the information on the treatment plans 
generated usually by a Treatment Planning System (TPS). 
Typically such plans provide the information about the treat-
ment fractions, describing the external beams of hadron therapy 
application. Parameters defined for every single beam spot in the 
plan are grouped into the beam sequence, where they are enumer-
ated using the control points. Control points checklist includes 
several information, i.e., particles energy, scan spot position, and 
number of monitor units. In addition, for each beam sequence, 
the information for particle type, position of the isocenter accord-
ing to the DICOM file and gantry, patient and table angles are 
defined. Flair is currently able to export the most frequently used 
beam sequence parameters into an external file, from which the 
special RTPLAN source routine reads and determines the entry 
source for the FLUKA simulations. While exporting data, Flair 
performs validation checks on the DICOM file using available 
control variables.
When defining the beam spot position, RTPLAN refers to its 
own coordinate system – Gantry Coordinate system and Isocenter 
Position. Flair is able to apply correct rotations and translations 
to the VOXEL structure, and as a result updates the FLUKA input 
file in order to prepare the fully functional ready-to-run simula-
tion for each single beam field. Further, postprocessing enables 
to combine simulation beam sequences outputs to one fractional 
dose file and to visualize it in RTViewer. Current work is focus-
ing on importing less frequently used RTPLAN parameters and 
simplifying the entire process of treatment plan re-simulation.
4.3. PeT scanner simulation  
Tools for FlUKa
PET is a commonly used imaging technique, based on detecting 
in coincidence the pair of annihilation photons created from the 
decay of a β+ emitter. Such positron-emitter nuclei are tradition-
ally inoculated to the patient by means of a radio-pharmaceutical 
drug, in order to analyze the metabolic activity of the body tissue 
and in the hope of detecting hints of unusual behavior from 
tumor cells. As an example, Fludeoxyglucose or 18F-FDG is a 
glucose-analog radio-pharmaceutical, where a normal hydroxyl 
group is substituted by the 18F radioactive isotope. This substance 
is used to study the glucose consumption of the cells.
Apart from its traditional use in nuclear medicine, PET 
is nowadays the only clinically available method for a non-
invasive monitoring of the dose delivery for hadron therapy. 
FigUre 16 | Flair interface of the PeT geometry tool.
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However, as mentioned in Section 3.1, there are still important 
concerns when using commercially available PET scanners for 
proton or ion beam treatment monitoring, usually compel-
ling to drastically redesign them. Monte Carlo codes are thus 
crucial to evaluate the performance of new PET prototypes and 
are an essential tool to infer the dose map from the positron-
emitter distribution. To ease the simulation of full PET scanner 
simulations with FLUKA, taking advantage of the latest devel-
opments on the models for beta-emitter production presented 
in Section 3, Flair incorporates a dedicated PET scanner tool, 
which covers all the steps from the creation of the geometry 
of the PET ring to the reconstruction of the image from the 
coincidence events.
4.3.1. Building the PET Geometry
With the aim of covering most of the collinear pairs of annihila-
tion photons, the geometry of PET scanners is generally com-
posed of an array of detector scintillators, describing a complete 
or partially opened cylindrical structure.
Consequently, PET detectors can be built by replication of 
simple rectangular parallelepiped sub-units. The PET geom-
etry tool exploits the replication capabilities of the FLUKA code 
(through its LATTICE cards) to generate a PET detector based 
on few simple geometrical parameters. The interface of the tool 
is intuitive, with illustrations that give a visual explanation of the 
meaning of each parameter (see Figure 16).
The natural cylindrical coordinate system of PET scanners 
is  exploited by associating the (R, θ, Z) coordinates with the 
(radial/depth, azimuthal, and axial) coordinates. The interface 
divides the required parameters in three levels:
•	 Block level, defined as the array of basic scintillators. The 
parameters that define the block are the number of scintillators 
in each direction, the elemental detector dimensions, and the 
separation among contiguous scintillators.
•	 Module level, taken as the array of blocks. The parameters for 
the module are the number of blocks in each direction coordi-
nate and the separation among neighboring blocks.
•	 Ring level, which defines the global properties of the PET. 
The parameters are, then, the number of modules along the 
ring, the radius of the ring, the vector defining the axis of the 
scanner, the center coordinates of the scanner, the material 
of the scintillator, the surrounding region where the scanner 
will be located and the opening angle, in case a partial ring is 
required.
The replication of the modules along the ring can be structured 
in partial or full rings, controlled by the opening angle θopen, which 
ranges from 0° to 180° (complete ring). The incorporation of 
partial rings is interesting for “in-beam” PET, where the scanner 
has to be integrated with other elements at the irradiation room 
(121). Based on the azimuthal dimensions of the module and θopen, 
the interface is capable of estimating the maximum number of 
modules that could fit in the available space.
From the previous parameters, the tool generates the input 
and geometry files (see Figure  17) providing the basic cards 
for a FLUKA simulation. Apart from the basic structure, any 
FigUre 17 | example of a MicroPeT P4 scanner built with the PeT 
geometry tool. The phantom is a high-quality, segmented mouse phantom 
(122, 123), imported to FLUKA voxels with the DICOM tool.
FigUre 18 | sinogram (left) and projection image (right) of the segmented mouse phantom of Figure 17, using a MicroPeT P4 scanner.
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additional elements of the detector should be included manually 
if necessary. This may include the septa for 2D acquisition mode, 
shielding elements, etc. The construction of the phantom target, 
the distribution of radioisotopes, or the beam structure should be 
further modeled by the user, depending on the specific require-
ments of the problem under study.
With the purpose of providing the user with a starting ground 
and facilitating the efficient implementation of a PET scanner, 
the interface presents several templates of commercial PET 
detectors, such as Ecat EXACT HR+ (CPS) (124), Ecat HRRT 
(Siemens) (125), Hi-Rez (Siemens) (126), Allegro (Philips) (127), 
GE Advance (GEMS) (128), MicroPET P4 (Concorde) (129), 
MicroPET Focus 220 (Siemens) (130), and Mosaic (Philips) 
(131). The parameters for such scanners can be further modified 
before building the geometry, thus serving as a base for detector 
design and optimizations.
4.3.2. Scoring of Coincident Events
In PET, the reconstruction problem consists of obtaining a tomo-
graphic slice image from a set of projections. The projections are 
built by delineating a set of parallel line of responses (LOR), the 
imaginary line that unites two coincidence events, through the 
2D phantom, assigning the integral of all the events registered 
along each LOR to a single pixel in the projection. Once several 
projections have been acquired, each of them corresponding to 
a different angle of the LOR with respect to the phantom, the 
PET reconstruction of the object can be performed. The set of 
projections at different angles is called a sinogram, which is a 
linearization of the original image (see Figure 18).
In FLUKA, a collection of scoring routines, complementary 
to the PET geometry tool, have been implemented, with the goal 
of acquiring the energy deposition events of the PET scintilla-
tors and the subsequent organization of such individual events 
in coincidence events. The scoring routines are divided in two 
steps. In a first step, FLUKA simulates the nuclear interactions 
and tracks the decaying particles through the phantom up to the 
PET scanner. The portion of energy of such particles deposited 
in the scintillators is then stored as an individual event, and all 
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the information regarding the event is dumped in a list mode 
output file. The scoring of individual events can be optimized 
with several editable parameters:
•	 the energy window, so only particles with a certain amount of 
deposited energy are scored;
•	 the minimum scoring time, that discards particles arriving 
at the PET before a time threshold;
•	 the time resolution of the detector;
•	 the dead-time of the detector, which is the time needed for the 
scintillator to process an event.
Accordingly, one output file with a list of individual events is 
generated per FLUKA run. In a second step, the set of list mode 
files is processed, and the coincidence events are produced. The 
coincidence events output file is organized in sinograms, in a 
Interfile 3.3 file, a standardized binary intermediate file format 
for nuclear medicine image data files (132).
The goal is to merge and organize the information produced by 
the PET data acquisition in a standardized way the user is already 
familiarized with, and which could be employed with external 
visualization or reconstruction software. For the sinogram output 
format, different parameters are available to customize the scor-
ing options: Arc Correction, Maximum Ring Difference (MRD), 
Number of Segments, Span and Mashing Factor. These parameters 
determine the 2D/3D acquisition mode and its characteristics 
(see Ref. (133) for further details). The values of these parameters 
can be conveniently modified by the user.
In addition, simple reconstruction algorithms are planned 
to be implemented in Flair, so the user can have an image of 
the object within the same interface. Two algorithms are under 
development: 2D Filtered Back-Projection (FBP) and Maximum-
Likelihood Expectation-Maximization (MLEM). On the one hand, 
FBP is a simple but fast algorithm, based on the Fourier Transform 
of the projection and interpolation in Fourier space. The 2D FT 
transform of the object obtained is then inverted to form the final 
image. MLEM, on the other hand, is an iterative method that best 
estimates the reconstruction image by maximizing the likelihood 
function. It finds the mean number of radioactive decays that 
better fits the sinogram with the highest likelihood. The output 
reconstructed image is then stored in USRBIN file, so the result 
can be further analyzed in Flair.
5. aPPlicaTiOn OF The FlUKa cODe 
FOr clinical calcUlaTiOns aT hiT 
anD cnaO
The FLUKA code has already been used to support clinical 
applications prior to the comprehensive extension of the Flair 
functionality to handle RT objects as described in Section 4.
Dedicated frameworks were implemented in the past at the 
Heidelberg Ion Beam Therapy Center (HIT, Germany) and the 
National Center of Oncological Hadrontherapy (CNAO, Italy) 
providing automated FLUKA MC simulations of clinical treat-
ment plans delivered by actively scanned proton and carbon ion 
beams (66, 134). Results obtained with these early frameworks 
have intensively been validated against clinical data and therefore 
provided a valuable reference for the benchmarking of several RT 
functionalities during the extension of Flair. The frameworks pro-
vide all functionality required for pre-processing of the DICOM 
RT input data as well as the postprocessing of the FLUKA output. 
Graphical user interfaces allow to access the fully automated data 
handling and are realized at HIT within the MeVisLab environ-
ment [www.mevislab.de (135)] and at CNAO with Matlab®. 
Physical and RBE-weighted dose distributions are calculated for 
individual treatment fields and the entire fraction using a global 
RBE of 1.1 for proton beams and a dedicated implementation of 
the LEM I framework, which is also used by the treatment plan-
ning system (TPS) (4, 75, 136) for carbon ion beams. During the 
physical and biological calculations dose-to-medium is always 
converted on-the-fly into dose-to-water, thus providing dose 
distributions in both formalisms, and dose-averaged LET can 
optionally be generated for proton beams. In order to assure con-
sistency with the TPS, the FLUKA physics settings are the same as 
used for the generation of the TPS basic data in water (41, 61, 65). 
For CT-based calculations, the MC patient model relies on the 
stoichiometric calibration of Ref. (1, 3) with proper facility and 
CT-number dependent adjustments of the electromagnetic and 
nuclear processes as in Ref. (2) for consistency with the CT-range 
calibration curves used by the TPS for all available CT protocols.
The RaySearch RayStation® TPS has been recently (2015) 
installed at CNAO, and the proton beam line is currently 
under commissioning. Being specifically thought to provide 
fast visualization environments and dose statistics tools, a TPS 
should represent the gold-standard interface to help physicists 
and physicians to also include MC simulations within the clinical 
routine. Therefore, in addition to the in-house Matlab® tools, 
an interface has been developed for converting FLUKA outputs 
in RTDOSE DICOM files. As an example, Figure  19 reports 
the physical dose distribution for the study of a 3-fields carbon 
ions plan (upper panels) for the irradiation of a retro-orbital 
metastasis. Depth–dose distributions (lower-left panels) and 
DVHs (lower-right panels) are also displayed. Good agreement 
has been found between MC and TPS calculated distributions for 
this challenging case both in terms of profiles and DVHs.
Figure 20 reports the RBE-weighted dose distribution (DRBE) 
of a clinical-like carbon ion therapy plan, delivered to the upper 
spine region in a single right-lateral field, calculated with the TPS 
(SIEMENS syngo® PT Treatment) and the HIT in-house MC 
framework (66) described above. Shown are the two-dimensional 
overlays of DRBE on top of the treatment planning CT image 
(Figure 20 upper panels), DRBE profiles along a representative line 
in beams eye view (Figure 20 lower-left panel) and the DVH for 
the PTV and the relevant organ at risk (spinal cord, Figure 20 
lower-right panel). We observe a good agreement between the 
TPS and the MC calculations, with the MC yielding a slightly 
higher DRBE level in the target region leading to an increase of 
D50 in the PTV of ≈2%, and of V10 in the spinal cord of ≈3%. 
The slight overestimation of RBE-weighted dose compared to the 
TPS calculation is attributed to differences in the mixed radiation 
field description of TPS and MC as discussed in more detail in 
Ref. (66).
Recently, Flair has been successfully applied at CNAO for 
performing dose forward calculations with proton beams. 
FigUre 19 | some snapshots taken from raystation® showing a comparison (in coronal view) between a syngo® 3-fields carbon ions plan vs. its Mc 
dose forward recalculation. Lower panels display the line dose and the DVH calculator tools. Differently from the TPS, which displays dose only within the 
“external-type” structure, the MC dose-to-water scoring is extended to the whole field of view of the CT scan.
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In Figure  14, an example of TPS- and MC-calculated dose 
distributions for a patient-like two fields treatment of a skull-
base chondrosarcoma is shown. The satisfactory agreement, as 
proven by the plotted dose differences (right panel in Figure 14), 
supports the future usage of Flair as standard re-calculation tool 
at CNAO.
6. cOnclUsiOn
The electromagnetic and nuclear models of FLUKA enable to 
reasonably well reproduce measured depth- and lateral-dose 
profiles in water for all the spectrum of ions of therapeutic inter-
est, making it the code of choice for generation of TPS input data 
at leading European centers in Germany and Italy, as well as a 
valuable tool to support analytical TPS developments of some 
commercial vendors. In the last years, special efforts have been 
devoted to improvements of the FLUKA nuclear interaction 
models, which provide benchmarked and reliable results for 
interaction cross sections and particle production by proton and 
ion beams at therapeutic energies. In particular, they allow to 
treat in a consistent way the transport and interaction of primary 
particles and all produced fragments, including transport of 
electromagnetic particles. All reaction generators share the same 
equilibrium particle emission, thus profiting together of the past 
and latest developments of the evaporation, fragmentation, and 
deexcitation models. Low energy nuclear models are of utmost 
importance for applications to in  vivo verification techniques. 
FLUKA is presently able to reproduce within experimental errors 
the production of β+ emitters by protons at energies of interest 
for therapy, and at 25% or better accuracy in the case of carbon 
projectiles. The newly developed and refined FLUKA models 
for prompt γ production were shown to reproduce reasonably 
discrete line cross sections as well as integral energy spectra 
and yield-vs.-depth data for proton and carbon ion beams. The 
general trends of the experimental cross-sectional data are con-
sistently reproduced by the models. This includes cross-sectional 
data of discrete lines for different targets, notably data for carbon, 
nitrogen, and oxygen nuclei.
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The relative shape of photon profiles as a function of depth as 
well as the absolute photon yield per primary proton and carbon 
ion (Figure 11) are well reproduced after the last revision of the 
experimental data (114). The comparisons with the experimental 
yield-depth data presented here suggest an accuracy of about 
15–20% for the prediction of absolute yields. The comparisons 
of simulated and measured energy spectra for proton beams 
(Figure 10) showed a very good agreement (mostly within 10%) 
for photon energies higher than 2 MeV. This is an energy range 
of interest for prompt-γ monitoring and spectroscopy. Progresses 
on nuclear interaction models are still ongoing, in particular for 
what concerns low mass ion beams, and a better treatment of 
spin/parity effects all along the reaction chain.
FLUKA’s physics model reliability is coupled with the versatile 
features of its Flair graphical interface, creating the necessary 
input directly from the computed tomography and radiotherapy 
files. This provides a powerful and user-friendly way to carry 
out Monte Carlo simulations for medical applications. Flair cur-
rently employs a fully functional DICOM CT/MT converter to 
VOXEL geometry, processing of the RTSTRUCT and RTDOSE 
modalities, and an automatic PET geometry generator. Work is 
ongoing on using the RTPLAN and toward the development of a 
Monte Carlo Treatment Planning System optimizer.
MC dose forward calculation has proven to be a valuable asset 
to support the development of commercial TP systems in the 
past. The reported implementations of the FLUKA code in auto-
mated workflow environments at HIT and CNAO are intensively 
used to study the impact of known shortcomings of the analytical 
approach in particle therapy treatment planning. They provide 
flexible and robust tools to address daily demands required for 
high quality patient treatment.
aUThOr cOnTriBUTiOns
GB: promoting the use and development of FLUKA in therapy 
applications, verifications of physical models, and production 
of text for the introduction. JB: verification and application of 
the code in clinical environment, production of text and figures 
for Section 5. TB: comparison of FLUKA models with dose 
profiles data, data analysis, and production of text and figures 
FigUre 20 | clinical-like carbon ion therapy plan delivered to the upper spine region in a single right-lateral field. Top: overlay views of RBE-weighted 
dose distributions obtained from the TPS (left) and the FLUKA framework (right) on the treatment planning CT image. Outlined are the PTV and the spinal cord. 
Bottom: comparison of TPS and MC RBE-weighted dose profiles along the white arrow drawn in the overlay views (left); dose volume histograms for PTV and spinal 
cord for both TPS and MC RBE-weighted dose distributions (right).
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